Ponazuril

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ponazuril
Ponazuril.png
Clinical data
Trade names Marquis
AHFS/Drugs.com FDA Professional Drug Information
Routes of
administration
Oral
ATCvet code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard 100.157.907
Chemical and physical data
Formula C18H14F3N3O6S
Molar mass 457.380 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Ponazuril (INN), sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona.[1][2] More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.

See also[edit]

References[edit]

  1. ^ Marquis FDA Professional Drug Information
  2. ^ MacKay, R. J.; Tanhauser, S. T.; Gillis, K. D.; Mayhew, I. G.; Kennedy, T. J. (2008). "Effect of intermittent oral administration of ponazuril on experimentalSarcocystis neuronainfection of horses". American Journal of Veterinary Research. 69 (3): 396–402. PMID 18312139. doi:10.2460/ajvr.69.3.396.